18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2163-2167

  Casulo, Carla ^a   Schöder, Heiko ^a   Feeney, John ^a   Lim, Remy ^a   Maragulia, Jocelyn ^a   Zelenetz, Andrew D ^a   Horwitz, Steven ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

FDG PET; Lymphoma and Hodgkin disease; Prognosis; Staging; T cell lymphoma

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LARGE CELL LYMPHOMA; LUNG; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SKIN; SPLEEN; T CELL LYMPHOMA; TREATMENT PLANNING; AGED; DIAGNOSTIC USE; LYMPHOMA, T-CELL; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884495605     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.767901     Document Type: Article

References (26)

1. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin-s lymphomas. J Natl Compr Canc Netw 2010; 8: 288-334.
2. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011; 29: 1844-1854.
3. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin-s lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 2009; 27: 1906-1914.
4. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
5. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 589-597.
6. Wu HB, Wang QS, Wang MF, et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 2010; 31: 195-200.
7. Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008; 87: 613-621.
8. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 1685-1690.
9. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 2008; 8: 94-99.
10. Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18FFDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008; 49: 1783-1789.
11. Bishu S, Quigley JM, Schmitz J, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 1531-1538.
12. Storto G, Di Giorgio E, De Renzo A, et al. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol 2010; 151: 195-197.
13. Otero HJ, Jagannathan JP, Prevedello LM, et al. CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol 2009; 193: 349-358.
14. Feeney J, Horwitz S, Gonen M, et al. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 2010; 195: 333-340.
15. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18FFDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin-s lymphoma. Haematologica 2000; 85: 613-618.
16. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin-s lymphoma. Ann Oncol 2002; 13: 1356-1363.
17. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
18. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523.
19. Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012; 30: 184-190.
20. Zinzani PL, GandolfiL, Broccoli A, et al. Midtreatment 18Ffluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011; 117: 1010-1018.
21. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDGPET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28: 1896-1903.
22. Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012; 53; 1876-1881.
23. Partridge S, Timothy A, O-Doherty MJ, et al. 2-Fluorine-18-fluoro- 2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin-s disease: Influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
24. Valencak J, Becherer A, Der-Petrossian M, et al. Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 2004; 89: 115-116.
25. Cahu X, Bodet-Milin C, Brissot E, et al. 18F-fluorodeoxyglucosepositron emission tomography before, during and after treatment in mature T/NK lymphomas: A study from the GOELAMS group. Ann Oncol 2011; 22: 705-711.
26. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin-s disease. Haematologica 2001; 86: 266-273.